在原发性局部治疗后前列腺特异性抗原升高的高危前列腺癌患者中,雄激素剥夺治疗联合多西他赛的随机临床试验
这项在法国28个中心开展的开放标签3期随机优效性试验,将254例原发局部治疗后PSA升高、无转移证据的高危前列腺癌患者随机分为ADT联合多西他赛组与单用ADT组。中位随访30.0个月时,两组中位PSA-PFS分别为20.3个月与19.3个月(HR 0.85,95%CI 0.62-1.16,P=0.31),差异无统计学意义。
要点
- ADT联合多西他赛组与单用ADT组的中位PSA-PFS分别为20.3个月与19.3个月,HR 0.85(95%CI 0.62-1.16,P=0.31)。
- 中位随访10.5年时,两组影像学PFS无显著差异(HR 1.03,95%CI 0.74-1.43,P=0.88)。
- ADT联合多西他赛组最常见的3或4级血液学毒性为中性粒细胞减少(48.0%)。
核心结论
- 与单用ADT相比,以治愈为目的的ADT联合多西他赛治疗未显著改善高危前列腺癌且PSA升高、无转移证据患者的前列腺特异性抗原无进展生存期。
研究设计与样本
- 开放标签、3期、随机优效性试验,比较ADT联合多西他赛与单用ADT,2003年6月4日至2007年9月25日在法国28个中心入组患者,末次随访为2017年4月12日,分析于2017年5月2日至7月31日进行。
- 共254例患者按1:1随机分组,按既往局部治疗和PSA水平倍增时间(≤6个月 vs >6个月)分层,采用意向性治疗分析。
- 干预为ADT(1年)联合多西他赛70 mg/m2(每3周,共6个周期),或单用ADT(1年)。
主要发现
- ADT联合多西他赛组中位年龄64岁,单用ADT组中位年龄66岁。
- 中位随访30.0个月时,ADT联合多西他赛组中位PSA-PFS为20.3个月(95%CI 19.0-21.6),单用ADT组为19.3个月(95%CI 18.2-20.8),HR 0.85(95%CI 0.62-1.16,P=0.31)。
- 中位随访10.5年时,两组影像学PFS无显著差异(HR 1.03,95%CI 0.74-1.43,P=0.88)。
- 总生存数据尚未成熟。
- ADT联合多西他赛组最常见的3或4级血液学毒性为中性粒细胞减少(125例中60例,48.0%)、发热性中性粒细胞减少(10例,8.0%)和血小板减少(4例,3.0%)。
局限性
- 总生存数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. OBJECTIVE: To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after primary local therapy and high-risk factors but no evidence of metastatic disease. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3, randomized superiority trial comparing ADT plus docetaxel vs ADT alone enrolled patients from 28 centers in France between June 4, 2003, and September 25, 2007; final follow-up was conducted April 12, 2017, and analysis was performed May 2 to July 31, 2017. Patients had undergone primary local therapy for prostate cancer, were experiencing rising PSA levels, and were considered to be at high risk of metastatic disease. Stratification was by prior local therapy and PSA-level doubling time (≤6 vs >6 months), and intention-to-treat analysis was used. INTERVENTIONS: Patients were randomly assigned to receive ADT (1 year) plus docetaxel, 70 mg/m2 (every 3 weeks [6 cycles]), or ADT alone (1 year). MAIN OUTCOMES AND MEASURES: The primary outcome was PSA progression-free survival (PSA-PFS). Secondary end points were PSA response, radiologic PFS, overall survival, safety, and quality of life. RESULTS: Overall, 254 patients were randomized (1:1) to the trial; median age, 64 years in the ADT plus docetaxel arm, 66 years in the ADT alone arm. At a median follow-up of 30.0 months, the median PSA-PFS was 20.3 (95% CI, 19.0-21.6) months in the ADT plus docetaxel arm vs 19.3 (95% CI, 18.2-20.8) months in the ADT alone arm (hazard ratio [HR], 0.85; 95% CI, 0.62-1.16; P = .31). At a median follow-up of 10.5 years, there was no significant between-arm difference in radiologic PFS (HR, 1.03; 95% CI, 0.74-1.43; P = .88). Overall survival data were not mature. The most common grade 3 or 4 hematologic toxic effects in the ADT plus docetaxel arm were neutropenia (60 of 125 patients [48.0%]), febrile neutropenia (10 [8.0%]), and thrombocytopenia (4 [3.0%]). There was no significant between-arm difference in overall quality of life. CONCLUSIONS AND RELEVANCE: Compared with ADT alone, combined ADT plus docetaxel therapy with curative intent did not significantly improve PSA-PFS in patients with high-risk prostate cancer and rising PSA levels and no evidence of metastatic disease. TRIAL REGISTRATION: French Health Products Safety Agency identifier: 030591; ClinicalTrials.gov identifier: NCT00764166.
引用
- Oudard S, Latorzeff I, Caty A, et al. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30703190. doi:10.1001/jamaoncol.2018.6607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。